Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD22+ Relapsed/Refractory B-ALL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06213636
What this trial is testing

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Who this might be right for
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more
Essen Biotech 75
Testing effectiveness (Phase 2)Looking for participantsNCT04781634
What this trial is testing

A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Who this might be right for
B-ALL
Chongqing Precision Biotech Co., Ltd 40
Not applicableLooking for participantsNCT06343090
What this trial is testing

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital 353
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Testing effectiveness (Phase 2)WithdrawnNCT03851081
What this trial is testing

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Allogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White Cells+5 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)UnknownNCT04714593
What this trial is testing

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia， B-Cell
Shanxi Province Cancer Hospital 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04499573
What this trial is testing

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

Who this might be right for
B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 50
Testing effectiveness (Phase 2)Looking for participantsNCT05674175
What this trial is testing

Co-administration of CART22-65s and huCART19 for B-ALL

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD 93
Very early researchLooking for participantsNCT06659653
What this trial is testing

Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

Who this might be right for
Acute Lymphoblastic Leukemia
Tan Jie 18
Testing effectiveness (Phase 2)UnknownNCT03185494
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 30
Early research (Phase 1)Looking for participantsNCT06445803
What this trial is testing

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed RemissionB-cell Lymphoma Refractory+1 more
Rong Tao 48
Testing effectiveness (Phase 2)UnknownNCT03614858
What this trial is testing

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

Who this might be right for
Leukemia, B-cell
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 20
Early research (Phase 1)Looking for participantsNCT07838714
What this trial is testing

Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Ruijin Hospital 18
Early research (Phase 1)Looking for participantsNCT06559189
What this trial is testing

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver 53
Testing effectiveness (Phase 2)Ended earlyNCT02227108
What this trial is testing

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Who this might be right for
B-Cell Pediatric ALL
MedImmune LLC 37
Early research (Phase 1)Looking for participantsNCT07108868
What this trial is testing

A Phase I Dose Finding Study of MB-CART2219.1

Who this might be right for
LymphomaCLLAcute Lymphoblastic Leukemia, Pediatric
University Hospital Tuebingen 36
Testing effectiveness (Phase 2)Looking for participantsNCT06081478
What this trial is testing

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-cell LymphomaDiffuse Large B Cell Lymphoma
Beijing Tongren Hospital 100
Early research (Phase 1)Ended earlyNCT05292898
What this trial is testing

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)Looking for participantsNCT07328503
What this trial is testing

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaB-All
National Cancer Institute (NCI) 20
Very early researchNot Yet RecruitingNCT06879262
What this trial is testing

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

Who this might be right for
R/R NHL
Tongji Hospital 60
Next Page